You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Baxter
Mallinckrodt
McKesson
AstraZeneca

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

Atazanavir - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Generic filers with tentative approvals for ATAZANAVIR
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial300MG/100MGTABLET; ORAL
  Start Trial  Start Trial200MGCAPSULE; ORAL
  Start Trial  Start Trial150MGCAPSULE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for atazanavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa ATAZANAVIR SULFATE atazanavir sulfate CAPSULE;ORAL 091673-004 Apr 22, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan ATAZANAVIR SULFATE atazanavir sulfate CAPSULE;ORAL 208177-001 Sep 24, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-004 Oct 16, 2006 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Bristol-myers Squibb EVOTAZ atazanavir sulfate; cobicistat TABLET;ORAL 206353-001 Jan 29, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-003 Jun 20, 2003 AB RX Yes No   Start Trial   Start Trial   Start Trial
Amneal ATAZANAVIR SULFATE atazanavir sulfate CAPSULE;ORAL 209717-002 Jun 1, 2020 AB RX No No   Start Trial   Start Trial   Start Trial
Amneal ATAZANAVIR SULFATE atazanavir sulfate CAPSULE;ORAL 209717-004 Jun 1, 2020 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Express Scripts
Harvard Business School
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.